Jazz Pharmaceuticals plc (JAZZ)

Jazz Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	4,087	4,069	3,834	3,659	3,094	2,364
Revenue Growth (YoY)	4.52%	6.12%	4.78%	18.26%	30.91%	9.34%
Cost of Revenue	321.4	310.7	284.13	267.13	217.68	148.92
Gross Profit	3,765	3,758	3,550	3,392	2,877	2,215
Selling, General & Admin	1,426	1,416	1,307	1,399	1,399	879.85
Research & Development	780.6	853.56	823.89	555.41	476.33	309.76
Amortization of Goodwill & Intangibles	632.91	627.31	608.28	599.17	525.77	259.58
Operating Expenses	2,839	2,897	2,739	2,553	2,401	1,449
Operating Income	925.88	861.64	810.73	839.14	475.26	765.46
Interest Expense	-315.53	-344.4	-354.54	-299.74	-280.57	-110.81
Interest & Investment Income	104.5	106.3	65.1	11.5	1.8	11.1
Earnings From Equity Investments	-0.93	-1.66	-3.01	-9.92	-0.71	-2.96
Currency Exchange Gain (Loss)	-9.01	-8.18	8.79	-19.01	-4.35	-3.27
EBT Excluding Unusual Items	704.91	613.71	527.07	521.97	191.43	659.52
Merger & Restructuring Charges	-139.82	-135.01	-151.45	-326.88	-304.99	-
Asset Writedown	-	-	-61.7	-133.65	-	-136.14
Legal Settlements	-172	-	-	-	-	-
Pretax Income	-512.27	468.69	294.92	-382.71	-113.55	272.13
Income Tax Expense	-107.43	-91.43	-119.91	-158.65	216.12	33.52
Earnings From Continuing Operations	-404.84	560.12	414.83	-224.06	-329.67	238.62
Net Income	-404.84	560.12	414.83	-224.06	-329.67	238.62
Net Income to Common	-404.84	560.12	414.83	-224.06	-329.67	238.62
Net Income Growth	-	35.02%	-	-	-	-54.41%
Shares Outstanding (Basic)	61	62	63	63	60	56
Shares Outstanding (Diluted)	61	66	72	63	60	57
Shares Change (YoY)	-12.92%	-8.41%	15.23%	4.77%	5.62%	-1.80%
EPS (Basic)	-6.63	9.06	6.55	-3.58	-5.52	4.28
EPS (Diluted)	-6.63	8.65	6.10	-3.58	-5.52	4.22
EPS Growth	-	41.75%	-	-	-	-53.57%
Free Cash Flow	1,265	1,358	1,068	1,243	750.87	884.64
Free Cash Flow Per Share	20.73	20.57	14.82	19.87	12.58	15.65
Gross Margin	92.14%	92.36%	92.59%	92.70%	92.97%	93.70%
Operating Margin	22.66%	21.18%	21.14%	22.93%	15.36%	32.39%
Profit Margin	-9.91%	13.77%	10.82%	-6.12%	-10.65%	10.10%
Free Cash Flow Margin	30.95%	33.37%	27.86%	33.97%	24.27%	37.43%
EBITDA	1,598	1,522	1,449	1,469	1,028	1,044
EBITDA Margin	39.11%	37.40%	37.80%	40.13%	33.22%	44.16%
D&A For EBITDA	672.53	660.07	638.7	629.47	552.48	278.25
EBIT	925.88	861.64	810.73	839.14	475.26	765.46
EBIT Margin	22.66%	21.18%	21.14%	22.93%	15.36%	32.39%
Effective Tax Rate	-	-	-	-	-	12.32%
Revenue as Reported	4,087	4,069	3,834	3,659	3,094	2,364
Advertising Expenses	-	107.4	92.2	108.8	161.5	99.6

Updated Aug 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q